04.29.14
Sanofi has increased its adoption of the Medidata Clinical Cloud as part of a company-wide initiative aimed at increasing productivity across its global R&D organization. Sanofi will now leverage Miedidata’s technology for risk-based monitoring of clinical trial sites, in addition to the solutions and analytics currently used.
Sanofi is developing an industry-wide approach for targeted monitoring of clinical trial sites and has selected Medidata’s targeted source document verification, Medidata RaveTSDV, to provide a scalable and auditable technology solution for its clinical operations and data management teams.
“We’re proud that Medidata’s cloud-based platform is supporting Sanofi in driving the effective and high-quality delivery of new medicines to patients worldwide,” said Glen de Vries, president of Medidata. “Sanofi is an early adopter of risk-based monitoring practices and has been quick to implement TransCelerate’s recommendations on this important methodology, streamlining the way clinical trials are conducted and monitored around the world.”
Sanofi is developing an industry-wide approach for targeted monitoring of clinical trial sites and has selected Medidata’s targeted source document verification, Medidata RaveTSDV, to provide a scalable and auditable technology solution for its clinical operations and data management teams.
“We’re proud that Medidata’s cloud-based platform is supporting Sanofi in driving the effective and high-quality delivery of new medicines to patients worldwide,” said Glen de Vries, president of Medidata. “Sanofi is an early adopter of risk-based monitoring practices and has been quick to implement TransCelerate’s recommendations on this important methodology, streamlining the way clinical trials are conducted and monitored around the world.”